FDA Leadership Change Sparks Pro-Life Concerns Over Abortion-Pill Regulation

On May 12, 2026, FDA Commissioner Dr. Marty Makary resigned. President Donald Trump appointed Deputy Commissioner for Human Foods Kyle Diamantas as acting commissioner, as the agency faces scrutiny over mifepristone regulation.

FDA Acting Commissioner Kyle Diamantas promises pro-life agenda, calls advocates

Pro-life groups fault Makary for keeping the 2023 deregulation that allows mail-order mifepristone up to ten weeks and for approving a generic version, saying the policy lacks safety guardrails. Main figures are Makary, acting commissioner Diamantas—who appeared on court filings for Planned Parenthood of Greater Orlando—and President Trump. The FDA began a safety study in September 2025; a generic was approved in May 2026; Makary resigned on May 12, 2026, and Diamantas took over the next day.

Pro-life groups praise FDA commissioner’s exit, flag acting leader’s Planned Parenthood role

The 2023 rule permits mail-order mifepristone up to ten weeks. Live Action claims over 7 million children have died; Texas Right to Life cites complications in >1 in 10 women. The FDA’s safety study has no recommendations yet.

Makary out as FDA commissioner after tumultuous tenure, pro-life criticism

The commissioner’s stance will decide whether the FDA reinstates in-person dispensing, tightens oversight, or keeps mail-order access, shaping state abortion policies and drug availability.

Makary resigns, acting FDA commissioner assures pro-life creds amid abortion pill case

Trump thanked Makary and called Diamantas “a very talented person.” HHS deputy assistant secretary Andrew Nixon said Diamantas is committed to the pro-life agenda and will consult stakeholders. A White House spokesperson noted Diamantas withdrew from the Planned Parenthood case after objections.

Makary resigns, acting FDA commissioner assures pro-life creds amid abortion pill case

Lichter praised Diamantas’s outreach. Harrington warned “personnel is policy” and doubted a full safety study given Diamantas’s Planned Parenthood ties. Rose called the appointment dangerous, and Dannenfelser urged immediate in-person dispensing.

FDA Acting Commissioner Kyle Diamantas promises pro-life agenda, calls advocates

• “Acting Commissioner Kyle Diamantas is personally committed to delivering on President Trump’s pro-life and pro-family agenda at the FDA,” — Andrew Nixon, Deputy Assistant Secretary for Media Relations, HHS

FDA Acting Commissioner Kyle Diamantas promises pro-life agenda, calls advocates

• “we cannot allow someone who represented Planned Parenthood to oversee rules surrounding the deadly abortion pill mifepristone that has killed MILLIONS of babies.” — Lila Rose, President, Live Action

Pro-life groups praise FDA commissioner’s exit, flag acting leader’s Planned Parenthood role

• “But personnel is policy, and the fact that Diamantas [reportedly] represented Planned Parenthood makes me skeptical that he will advocate for the full mifepristone safety study.” — Mark Harrington, President, Created Equal

FDA Acting Commissioner Kyle Diamantas promises pro-life agenda, calls advocates

• “we must return immediately to the [first] Trump administration standard of in-person dispensing to protect women from coercion and abuse and allow the enforcement of pro-life state laws.” — Marjorie Dannenfelser, President, Susan B. Anthony Pro-Life America

Pro-life groups praise FDA commissioner’s exit, flag acting leader’s Planned Parenthood role

Sources differ on Diamantas’s Planned Parenthood role: some call him a junior associate who withdrew after objections; others note his name on court filings, implying formal counsel. The FDA’s safety study remains pending with no regulatory outcome.

Daily Caller

The administration must nominate a permanent FDA commissioner, a decision likely to be scrutinized by pro-life groups and Senate Republicans. Louisiana’s lawsuit challenging mail-order mifepristone proceeds in the Fifth Circuit and before the Supreme Court, with a ruling expected soon.

Makary resigns, acting FDA commissioner assures pro-life creds amid abortion pill case